• Publications
  • Influence
Outcome in a patient with systemic lupus erythematosus and concurrent chronic hepatitis B infection
A 35-year-old Caucasian woman with proven systemic lupus erythematosus (SLE) had been effectively managed with hydroxychloroquine and methylprednisolone for many years. In 2005 she was admitted to
Diffuse mesangial IgA glomerulonephritis in a patient with rheumatoid arthritis: a possible extra-articular manifestation in rheumatoid arthritis
The case of a 42-year-old Caucasian man with RA and diffuse mesangial IgA glomerulonephritis proven by renal biopsy is presented, and full clinical and laboratory remission of RA and IgA Glomerul onephritis was achieved.
Is the presence of sleep apnoea-hypopnoea syndrome a precursor for gout?
A positive relationship between sleep variables, including the presence of snoring, snorting and daytime sleepiness, and high levels of serum uric acid is found, and it is indicated that both indexes of the UA/Cr and plasma adenosine during sleep reflect the same purine catabolic pathway associated with tissue hypoxia in these patients.
Erythema Nodosum as a Reactive Vasculitis, Induced by Letrozole the Rapyin a Patient with Hormone - Sensitive Breast Cancer
There are few cases of necrotizing or leucocytoclasticvasculitis induced by aromatase inhibitors, so this side effect of Letrozole is reported as rare cause for erythema nodosum.
A Patient with Ankylosing Spondylitis, Parkinson’s Diseaseand Seminoma Testis - Three Different Diagnoses or One Disease with Multiple Faces
Ankylosing Spondylitis is an autoimmune inflammatory joint disease, disabling when not treated adequately, and biologics can cause neoplastic processes in the time of treatment, but whether they can lead to drug-induced Parkinson disease, or no not, is not elucidated.
[The effect of benzbromarone on hyperlipidemia in gout].
The follow up of 38 men with proved gout established an increase mainly of endogenous triglycerides and cholesterol, which allows benzbromarone to be recommended for the treatment of hyperlipidemia in gout which will lead to a decrease of the vascular complications and mortality in g out.